ClinicalTrials.gg
Active, not recruitingNCT04165993Updated Sep 21, 2023

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

A Phase 2 interventional study of Concurrent chemotherapy and KN026 and KN026 monotherapy in Metastatic Breast Cancer, sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd (part of Alphamab Oncology) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Enrollment
1,022nd of 1,519
68 · median 120
Started
2019
with 113 others
Phase 2
493 of 1,928
243 open now
Primary completion
2021-05
later than 10 of 1,063 live
Registered
560th of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 1,022nd largest by enrollment of the 1,519 interventional ones that give a count, is one of 114 that started in 2019, is one of 493 in phase 2, reaches primary completion later than 10 of the 1,063 other live ones, and was the 560th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

861 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is an open-label, three-cohort phase 2 study of KN026 in subjects with advanced breast Cancer.

Read the detailed description

KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, leading to a dual HER2 signal blockade.The HER2- positive mBC subjects without systemic treatment will be enrolled in cohort 1 and received 30 mg/kg KN026 and docetaxol. The HER2 low expression and hormone-receptor positive mBC subjects failed standard chemotherapy and hormone therapy will be enrolled in cohort 2 and received 30 mg/kg KN026 monotherapy. The HER2 low expression and hormone-receptor negative/weak positive mBC subjects failed standard chemotherapy will be enrolled in cohort 3 and received 30 mg/kg KN026 and 5 mg/kg KN046

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject >= 18 years
  • Histologically/ confirmed, locally advanced unresectable or breast cancer
  • score 0 or 1
  • >3 months
  • According to the definition of RECIST1.1, the patient has at least one
  • Adequate organ function prior to start treatment with KN026
  • Able to understand, voluntarily participate and willing to sign the ICF

Exclusion criteria

Exclusion Criteria:

  • Accepted any other anti-tumor drug therapies within 4 weeks before fist dose
  • Accepted radiotherapy within 4 weeks before enrollment
  • Subjects are eligible with clinically controlled and stable neurologic function >= 4 weeks, which is no evidence of CNS disease progression; Subjects with spinal cord compression and cancerous meningitis are not eligible
  • Pregnant or nursing females;or intend pregnancy within this study period or within 6 monthes after the end of this study
  • History of immunodeficiency, including positive or other acquired, congenital immunodeficiency disease, or a history of organ transplantation
  • History of immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or a history of organ transplantation
  • Cavity effusion (pleural effusion, ascites, pericardial effusion, etc.) are not well controlled, and need locally treatment or repeated drainage
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Concurrent chemotherapy and KN026

    KN026 combined with docetaxol

    Drug: Concurrent chemotherapy and KN026

  • Experimental
    KN026 monotherapy

    KN026 monotherapy

    Drug: KN026 monotherapy

  • Experimental
    A combination treatment of KN026 and KN046

    KN026 combined with KN046

    Drug: KN026 combination

Interventions

  • DrugConcurrent chemotherapy and KN026

    Drug page: Anbenitamab

    30 mg/kg Q3W KN026 75 mg/m2 docetaxol

    Also known as: docetaxol

  • 30 mg/kg Q3W KN026

    Also known as: KN026

  • DrugKN026 combination

    Drug page: Anbenitamab

    30 mg/kg Q3W KN026 5 mg/kg Q3W KN046

    Also known as: KN046

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Objective response rate (ORR) per RECIST 1.1 criteria according to investigators assessment

    Time frame: Throughout the duration of the study; up to 2 years

  2. Duration of response (DOR)

    Duration of response (DOR) per RECIST 1.1 criteria according to investigators assessment

    Time frame: up to 2 years

Secondary outcomes

  1. Percentage of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest

    AEs, SAEs

    Time frame: Throughout the duration of the study

  2. Progression free survival (PFS) rates

    Progression free survival (PFS) rates

    Time frame: 6 months and 12 months

  3. Overall survival (OS) rates

    Overall survival (OS) rates

    Time frame: 6 months and 12 months

  4. durable benefit rate (DBR)

    durable benefit rate (DBR)

    Time frame: DBR calculated as the proportion of subjects with best overall response of CR, PR, or SD ≥24 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in May 2021, 16 months.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 16 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2019
First posted
Nov 18, 2019
StartActual
Dec 31, 2019
Primary completionActual
May 27, 2021
CompletionEst.
Dec 31, 2025
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04165993
Responsible party
Sponsor
First posted
Nov 18, 2019
Start date
Dec 31, 2019
Primary completion
May 27, 2021
Completion
Dec 31, 2025 (estimated)
Last update
Sep 21, 2023

Study contacts

Qingyuan Zhang, Professor
principal investigator · The Second Affiliated Hospital of Harbin Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anbenitamab

Start the discussion